TY - JOUR
T1 - Pancreatic ductal adenocarcinoma
T2 - the latest on diagnosis, molecular profiling, and systemic treatments
AU - Bugazia, Doaa
AU - Al-Najjar, Ebtesam
AU - Esmail, Abdullah
AU - Abdelrahim, Saifudeen
AU - Abboud, Karen
AU - Abdelrahim, Adham
AU - Umoru, Godsfavour
AU - Rayyan, Hashem A
AU - Abudayyeh, Ala
AU - Al Moustafa, Ala-Eddin
AU - Abdelrahim, Maen
N1 - Publisher Copyright:
Copyright © 2024 Bugazia, Al-Najjar, Esmail, Abdelrahim, Abboud, Abdelrahim, Umoru, Rayyan, Abudayyeh, Al Moustafa and Abdelrahim.
PY - 2024
Y1 - 2024
N2 - Pancreatic ductal adenocarcinoma (PDAC) is currently the fourth leading cause of death in the United States and is expected to be ranked second in the next 10 years due to poor prognosis and a rising incidence. Distant metastatic PDAC is associated with the worst prognosis among the different phases of PDAC. The diagnostic options for PDAC are convenient and available for staging, tumor response evaluation, and management of resectable or borderline resectable PDAC. However, imaging is crucial in PDAC diagnosis, monitoring, resectability appraisal, and response evaluation. The advancement of medical technologies is evolving, hence the use of imaging in PDAC treatment options has grown as well as the utilization of ctDNA as a tumor marker. Treatment options for metastatic PDAC are minimal with the primary goal of therapy limited to symptom relief or palliation, especially in patients with low functional capacity at the point of diagnosis. Molecular profiling has shown promising potential solutions that would push the treatment boundaries for patients with PDAC. In this review, we will discuss the latest updates from evidence-based guidelines regarding diagnosis, therapy response evaluation, prognosis, and surveillance, as well as illustrating novel therapies that have been recently investigated for PDAC, in addition to discussing the molecular profiling advances in PDAC.
AB - Pancreatic ductal adenocarcinoma (PDAC) is currently the fourth leading cause of death in the United States and is expected to be ranked second in the next 10 years due to poor prognosis and a rising incidence. Distant metastatic PDAC is associated with the worst prognosis among the different phases of PDAC. The diagnostic options for PDAC are convenient and available for staging, tumor response evaluation, and management of resectable or borderline resectable PDAC. However, imaging is crucial in PDAC diagnosis, monitoring, resectability appraisal, and response evaluation. The advancement of medical technologies is evolving, hence the use of imaging in PDAC treatment options has grown as well as the utilization of ctDNA as a tumor marker. Treatment options for metastatic PDAC are minimal with the primary goal of therapy limited to symptom relief or palliation, especially in patients with low functional capacity at the point of diagnosis. Molecular profiling has shown promising potential solutions that would push the treatment boundaries for patients with PDAC. In this review, we will discuss the latest updates from evidence-based guidelines regarding diagnosis, therapy response evaluation, prognosis, and surveillance, as well as illustrating novel therapies that have been recently investigated for PDAC, in addition to discussing the molecular profiling advances in PDAC.
KW - computed tomography (CT)
KW - magnetic resonance imaging (MRI)
KW - molecular profiling
KW - pancreatic cancer novel therapy
KW - pancreatic cancer treatments
KW - pancreatic ductal adenocarcinoma
KW - pancreatic neoplasm
UR - http://www.scopus.com/inward/record.url?scp=85198529184&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85198529184&partnerID=8YFLogxK
U2 - 10.3389/fonc.2024.1386699
DO - 10.3389/fonc.2024.1386699
M3 - Review article
C2 - 39011469
SN - 2234-943X
VL - 14
SP - 1386699
JO - Frontiers in Oncology
JF - Frontiers in Oncology
M1 - 1386699
ER -